# US 2023/0398127 A1 · Use of combined oral contraceptives containing nomegestrol acetate and estradiol

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0398127 A1
- Document ID: US20230398127A1
- Status: Published application
- Kind: A1
- Application number: 18/031,748
- Filed: 2021-10-12
- Published: 2023-12-14
- Earliest claimed: 2020-10-16
- Assignees: Theramex Hq UK Limited
- Applicants: Theramex Hq UK Limited
- Inventors: Mitra BOOLELL
- Web page: https://patentgrep.com/patent/US20230398127A1

## CPC

- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/2027: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 31/565: not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K 31/567: substituted in position 17 alpha, e.g. mestranol, norethandrolone
- A61K 31/57: substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K 31/575: substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 15/18: Feminine contraceptives
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to the use of compositions comprising nomegestrol acetate (NOMAC) and estradiol or an ester thereof. The compositions are for use in reducing the risk of venous thromboembolism (VTE) associated with the use of combined oral contraceptives (COC). The compositions may be used in methods of contraception and/or methods of treatment in women having conditions linked to menstruation and/or fertility.

## Claims

### Claim 1

A composition for use in reducing the risk of venous thromboembolism associated with the use of combined oral contraceptives, wherein the composition comprises nomegestrol acetate and estradiol or an ester thereof.

### Claim 2 (depends on 1)

The composition for use according to claim 1, wherein the risk of deep vein thrombosis is reduced.

### Claim 3 (depends on 1, 2)

The composition for use according to claim 1 or claim 2, wherein the risk of pulmonary embolism is reduced.

### Claim 4

The composition for use according to any one of the preceding claims, wherein the risk of venous thromboembolism is reduced relative to a combined oral contraceptive containing levonorgestrel; and optionally ethinylestradiol.

### Claim 5

The composition for use according to any one of the preceding claims, wherein the risk of venous thromboembolism is reduced by at least 40%.

### Claim 6

The composition for use according to any one of the preceding claims, wherein the Hazard Ratio is 0.5-0.6.

### Claim 7

The composition for use according to any one of the preceding claims, wherein the composition is administered to a woman or women of child-bearing age as a means of contraception.

### Claim 8

The composition for use according to any one of the preceding claims, wherein the composition is administered to a woman or women for a non-contraceptive use.

### Claim 9 (depends on 8)

The composition for use according to claim 8 wherein the non-contraceptive use is selected from (i) the treatment of a condition selected from painful menstrual bleeding, heavy and/or prolonged menstrual bleeding, acne, ovarian cysts, polycystic ovary syndrome, premenstrual syndrome, endometriosis, or premenstrual dysphoric disorder; and/or (ii) menstrual cycle regulation.

### Claim 10

The composition for use according to any one of the preceding claims, wherein the composition is administered to a woman or women identified as at increased risk of venous thromboembolism.

### Claim 11

The composition for use according to any one of the preceding claims, wherein the composition is administered to a woman or women 35 years of age or above.

### Claim 12

The composition for use according to any one of the preceding claims, wherein the composition is administered to a woman or women having a body mass index in excess of 30 kg/m2 and/or a woman or women with diabetes.

### Claim 13

The composition for use according to any one of the preceding claims, wherein the composition is administered to a woman or women having a condition selected from: cancer; systemic lupus erythematosus; haemolytic uraemic syndrome; chronic inflammatory bowel disease, optionally Crohn's disease or ulcerative colitis; and sickle cell disease.

### Claim 14

The composition for use according to any one of the preceding claims, wherein the composition is administered to a woman or women who has/have not received prior combined oral contraceptive treatment.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The composition for use according to any one of claims 1-13, wherein the composition is administered to a woman or women who have previously received combined oral contraceptive treatment.

### Claim 16

The composition for use according to any one of the preceding claims, wherein the nomegestrol acetate and estradiol or ester thereof are present in the composition in a weight ratio of approximately 1.67 to 1.

### Claim 17

The composition for use according to any one of the preceding claims, wherein the nomegestrol acetate is present in an amount ranging from about 1.5 mg to about 3.75 mg.

### Claim 18

The composition for use according to any one of the preceding claims, wherein the estradiol or ester thereof is present in an amount ranging from about 0.5 mg to about 3 mg.

### Claim 19

The composition for use according to any one of the preceding claims, wherein the estradiol is 17β-estradiol; optionally wherein the 17β-estradiol is in hemihydrate form.

### Claim 20

The composition for use according to any one of the preceding claims, wherein the nomegestrol acetate is present in an amount of about 2.5 mg and the estradiol is present in an amount of about 1.5 mg.

### Claim 21

The composition for use according to any one of the preceding claims, wherein the composition is administered daily for a period of 21 to 28 days; optionally for a period of 24 consecutive days.

### Claim 22

The composition for use according to any one of the preceding claims, wherein the composition is in the form of plain or film-coated tablets, sugar-coated tablets, soft gelatin capsules, wafer capsules, pills, cachets or powders.

### Claim 23

The composition for use according to any one of the preceding claims, wherein the composition further comprises at least one excipient selected from: lactose monohydrate; microcrystalline cellulose (E460); crospovidone (E1201); talc (E553b); magnesium stearate (E572); and colloidal anhydrous silica; or any combination thereof.

### Claim 24

The composition for use according to any one of the preceding claims wherein the composition comprises: 2.5 mg nomegestrol acetate; 1.5 mg 17β-estradiol; 57.7 mg lactose monohydrate; 14 mg microcrystalline cellulose; 2.4 mg crospovidone; 0.7 mg talc; 0.7 mg magnesium stearate, and 0.44 mg colloidal anhydrous silica.

### Claim 25

The composition for use according to any one of the preceding claims, wherein the composition is provided as a pharmaceutical kit comprising a plurality of dosage units and optionally at least one placebo.

### Claim 26

Use of a composition comprising nomegestrol acetate and estradiol or an ester thereof as a contraceptive; wherein the risk of venous thromboembolism associated with the use of combined oral contraceptives is reduced.

### Claim 27

A method of contraception, wherein the method comprises administering to a woman a composition comprising nomegestrol acetate and estradiol or an ester thereof, wherein the risk of venous thromboembolism associated with the use of combined oral contraceptives is reduced in the woman administered the composition.

### Claim 28

A composition for use in a method of treating a condition selected from: painful menstrual bleeding; heavy and/or prolonged menstrual bleeding; acne; ovarian cysts; polycystic ovary syndrome; premenstrual syndrome; endometriosis; and premenstrual dysphoric disorder, wherein the composition comprises nomegestrol acetate and estradiol or an ester thereof; and wherein the risk of venous thromboembolism associated with the use of combined oral contraceptives is reduced.

### Claim 29

A method of reducing the risk of venous thromboembolism associated with the use of combined oral contraceptives, wherein the method comprises administering to a woman a composition comprising nomegestrol acetate and estradiol or an ester thereof.
